Compare · ALGN vs POAI
ALGN vs POAI
Side-by-side comparison of Align Technology Inc. (ALGN) and Predictive Oncology Inc. (POAI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALGN and POAI operate in Industrial Specialties (Health Care), so they compete in similar markets.
- ALGN is the larger of the two at $12.76B, about 1028.1x POAI ($12.4M).
- Over the past year, ALGN is down 6.9% and POAI is down 61.1% - ALGN leads by 54.1 points.
- ALGN has hit the wire 16 times in the past 4 weeks while POAI has been quiet.
- ALGN has more recent analyst coverage (25 ratings vs 2 for POAI).
- Company
- Align Technology Inc.
- Predictive Oncology Inc.
- Price
- $174.96-1.80%
- $5.49-0.18%
- Market cap
- $12.76B
- $12.4M
- 1M return
- +6.20%
- -16.18%
- 1Y return
- -6.93%
- -61.06%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2001
- News (4w)
- 16
- 0
- Recent ratings
- 25
- 2
Align Technology Inc.
Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.
Predictive Oncology Inc.
Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company operates in three segments: Helomics, Soluble, and Skyline. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers STREAMWAY System, a wall-mounted fully automated system that disposes suction fluid providing uninterrupted performance for physicians while virtually eliminating healthcare workers' exposure to infectious fluids collected during surgical and other patient procedures, as well as proprietary cleaning fluid and filters to users of its systems. The company also provides contract research organization (CRO) and AI-driven predictive models of tumor drug response to improve clinical outcomes to assist pharmaceutical, diagnostic, and biotech industries; and soluble and stable formulations for proteins, including vaccines, antibodies, and other protein therapeutics, as well as develops tumor models for precision cancer therapy and drug development. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence (AI) applied to diseases databases. The company sells its medical device products directly to hospitals and other medical facilities through employed sales representatives, independent contractors, and distributors. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
Latest ALGN
- Align Technology Awards Funding to Universities Worldwide for Advancing Orthodontic and Dental Research
- SEC Form SD filed by Align Technology Inc.
- Director Vitalone Britt J. converted options into 1,443 shares (SEC Form 4)
- Director Siegel Susan E converted options into 1,745 shares, increasing direct ownership by 19% to 10,723 units (SEC Form 4)
- Director Saia Andrea Lynn converted options into 1,745 shares, increasing direct ownership by 11% to 17,318 units (SEC Form 4)
- Director Poul Mojdeh converted options into 1,745 shares, increasing direct ownership by 97% to 3,553 units (SEC Form 4)
- Director Myong Anne converted options into 1,745 shares, increasing direct ownership by 22% to 9,830 units (SEC Form 4)
- Director Larkin C Raymond Jr converted options into 2,326 shares, increasing direct ownership by 9% to 27,454 units (SEC Form 4)
- Director Dallas Kevin J converted options into 1,745 shares, increasing direct ownership by 12% to 16,168 units (SEC Form 4)
- Director Lacob Joseph converted options into 1,745 shares (SEC Form 4)
Latest POAI
- SEC Form S-8 filed by Predictive Oncology Inc.
- Predictive Oncology Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Chief Executive Officer Vennare Raymond F covered exercise/tax liability with 2,373 shares, decreasing direct ownership by 27% to 6,418 units (SEC Form 4)
- Predictive Oncology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Predictive Oncology Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
- SEC Form EFFECT filed by Predictive Oncology Inc.
- Predictive Oncology Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 424B3 filed by Predictive Oncology Inc.
- SEC Form 424B3 filed by Predictive Oncology Inc.
- Predictive Oncology Inc. filed SEC Form 8-K: Other Events